Ian Orme

Affiliations: 
Colorado State University, Fort Collins, CO 
Area:
Immunology, Microbiology Biology
Google:
"Ian Orme"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Tiwari S, Dutt TS, Chen B, et al. (2020) BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosis. Vaccine
Aceves-Sánchez MJ, Flores-Valdez MA, Shanley C, et al. (2018) Vaccination of guinea pigs with BCGΔBCG1419c transiently reduces hematogenous spread of M. tuberculosis to the spleen. Pathogens and Disease. 76
Orme IM, Henao-Tamayo MI. (2018) Trying to See the Forest through the Trees: Deciphering the Nature of Memory Immunity to. Frontiers in Immunology. 9: 461
Shanley CA, Henao-Tamayo MI, Bipin C, et al. (2018) Biology of clinical strains of Mycobacterium tuberculosis with varying levels of transmission. Tuberculosis (Edinburgh, Scotland). 109: 123-133
King TH, Shanley CA, Guo Z, et al. (2017) A novel yeast-based therapeutic vaccine for tuberculosis: GI-19007. Clinical and Vaccine Immunology : Cvi
Orme IM. (2017) Pillars Article: The Kinetics of Emergence and Loss of Mediator T Lymphocytes Acquired in Response to Infection with Mycobacterium Tuberculosis. J. Immunol. 1987. 138: 293-298. Journal of Immunology (Baltimore, Md. : 1950). 199: 833-838
Orme IM, Ordway DJ. (2016) Mouse and Guinea Pig Models of Tuberculosis. Microbiology Spectrum. 4
Henao-Tamayo MI, Obregón-Henao A, Arnett K, et al. (2015) Effect of bacillus Calmette-Guérin vaccination on CD4+Foxp3+ T cells during acquired immune response to Mycobacterium tuberculosis infection. Journal of Leukocyte Biology
Henao-Tamayo M, Shanley CA, Verma D, et al. (2015) The Efficacy of the BCG Vaccine against Newly Emerging Clinical Strains of Mycobacterium tuberculosis. Plos One. 10: e0136500
Bai X, Shang S, Henao-Tamayo M, et al. (2015) Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America. 112: 5111-6
See more...